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Summary
 
Antibody-mediated neutralization of human immunodeficiency virus type–1 (HIV-1) is
thought to function by at least two distinct mechanisms: inhibition of virus–receptor binding,
and interference with events after binding, such as virus–cell membrane fusion. Here we show,
by the use of a novel virus–cell binding assay, that soluble CD4 and monoclonal antibodies to
all confirmed glycoprotein (gp)120 neutralizing epitopes, including the CD4 binding site and
the V2 and V3 loops, inhibit the adsorption of two T cell line–adapted HIV-1 viruses to CD4
 
1
 
cells. A correlation between the inhibition of virus binding and virus neutralization was ob-
served for soluble CD4 and all anti-gp120 antibodies, indicating that this is a major mechanism
of HIV neutralization. By contrast, antibodies specific for regions of gp120 other than the CD4
binding site showed little or no inhibition of either soluble gp120 binding to CD4
 
1
 
 cells or sol-
uble CD4 binding to HIV-infected cells, implying that this effect is specific to the virion–cell
interaction. However, inhibition of HIV-1 attachment to cells is not a universal mechanism of
neutralization, since an anti-gp41 antibody did not inhibit virus–cell binding at neutralizing
concentrations, implying activity after virus–cell binding.
 
N
 
eutralization of enveloped viruses by antibody alone,
in the absence of other factors such as complement
and antibody-dependent cellular cytotoxicity, is mediated
by various mechanisms, including viral aggregation, the in-
hibition of virus binding to its cellular receptor, and inter-
ference with later events such as virus–cell membrane fu-
sion (for review see references 1 and 2). Of these diverse
mechanisms, the inhibition of virus binding to its target cell
is conceptually simple, in that a virus that cannot bind can-
not infect, but is considered to occur only rarely (1, 2). In-
hibition of virus–cell binding has nevertheless been impli-
cated as a mechanism of antibody-mediated neutralization for
several enveloped viruses: Newcastle disease virus (3), rhi-
novirus (4), mouse mammary tumor virus (5), visna virus
(6), and HIV-1 (7–11). Most of these studies were carried
out either with polyclonal antisera, or a single mAb, and
the precise relationship between neutralization and inhibi-
tion of virus–cell binding was generally not well estab-
lished. Thus, the relative importance of this mechanism of
virus neutralization remains unclear.
Neutralizing activity in the serum of HIV-1–infected in-
dividuals is directed predominantly to the surface envelope
glycoprotein (gp)120,
 
1
 
 although neutralization can also be
mediated by a transmembrane glycoprotein (gp41)–specific
fraction of antibodies (for review see references 12–15).
The anti-gp120 neutralizing response has been mapped by
the use of mAbs of rodent, chimpanzee, and human origin,
allowing the identification of a number of neutralization
epitope clusters on gp120 and gp41 (12, 13). The majority
of the neutralizing activity against T cell line–adapted (TCLA)
viruses in human antisera is reactive with two regions of
gp120; the CD4 binding pocket and associated structures
(known as the CD4 binding site or CD4bs), and the V3
loop (16). Other confirmed gp120-specific neutralizing ac-
tivity is directed to the hypervariable loops V1/V2, or to
complex, discontinuous epitopes clustered around the base
of the variable loops (17–20). By contrast with most TCLA
viruses, primary isolates are generally difficult to neutralize;
higher concentrations of antibody are required and fewer
neutralizing epitopes are available (12, 13, 15).
 
1
 
Abbreviations used in this paper:
 
 bs, binding site; GM, growth medium; gp,
glycoprotein; i, induced; s, soluble; TCLA, T cell line adapted; WB, wash
buffer.
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Little is understood of the mechanisms by which anti-
bodies neutralize HIV-1. Antibodies to the V3 loop of
gp120 have long been assumed to inhibit HIV infection at
a stage after virus–cell binding, since these antibodies in-
hibit soluble (s)gp120-CD4 binding weakly or not at all
(21–23). However, direct evidence to support postbinding
activity is limited (24–26). A cluster of gp120-specific
mAbs, including some which recognize the V3 loop and
related structures, has been demonstrated to induce gp120
dissociation from gp41 on TCLA HIV-1, suggesting that
this may contribute to viral inactivation (27). Recently it
has been shown that neutralizing anti-gp120 mAbs to re-
gions other than the CD4bs, including some specific for
the V3 loop, inhibit the interaction of sgp120 with the
HIV-1 coreceptor CCR5 (28, 29). These studies imply
that HIV-1 neutralization may be mediated primarily by
inhibition of the interactions between gp120 and the CD4
coreceptor complex.
The binding to CD4 of recombinant, monomeric sgp120,
derived from TCLA viruses, is blocked by anti-CD4bs an-
tibodies, implying that their mechanism of neutralization
may be based, at least in part, on competition for virus–recep-
tor binding (8, 30, 31). However, the interaction between
sgp120 and sCD4 or sgp120 and CD4
 
1
 
 cells is unlikely to
adequately represent the true virus–cell binding interaction,
since the conformation and quaternary structure of sgp120
and gp41-associated, oligomeric gp120 are different (32–
34), as is the valency of potential interaction sites with cel-
lular proteins. Moreover, the binding affinity for CD4 of
oligomeric, gp41-associated gp120 may be substantially
lower than that of monomeric sgp120 from the same viral
background (35–37). Direct measurement of virion bind-
ing to CD4
 
1
 
 cells is obviously the assay of choice for the
analysis of HIV-1–cell binding and the inhibition of this
process by cellular and viral ligands. Few studies have re-
ported the inhibition of HIV virion binding to CD4
 
1
 
 cells
by antibodies. McDougal et al. demonstrated that neutral-
izing human antisera prevented viral adsorption to CD4
 
1
 
cells (7), Posner et al. observed that a neutralizing anti-
CD4bs mAb inhibited HIV-1–cell binding in a dose-
dependent manner (10), and Bahraoui et al. found partial
inhibition of HIV–1 cell binding by two anti-V3 loop–spe-
cific mAbs (22). However, one drawback with the analyses
of HIV-1–cell binding carried out in these studies is that
sgp120 present in the virus preparation or released from
virions during the assay would also bind to the CD4
 
1
 
 cells,
and would be detected with the anti-gp120–reactive anti-
bodies used. Assuming that sgp120 has a higher affinity
than virion gp120, this would then bias the assay readout in
favor of the sgp120–CD4 interaction and prevent a precise
analysis of virion–cell interactions. Moreover, the prebind-
ing of neutralizing mAbs or sCD4 to virion gp120 is likely
to influence later detection of virus by gp120-reactive anti-
bodies.
To clarify the influence of neutralizing mAbs on HIV-1–
cell binding, we analyzed the ability of a panel of neutraliz-
ing mAbs specific for different gp120 neutralizing epitopes
to inhibit HIV-1–cell binding, using a novel assay in which
virion–cell binding is measured directly without contami-
nation of the detection signal by sgp120. We found that all
gp120-specific mAbs tested inhibited virus–cell binding,
and that this inhibition correlated strongly with virus neu-
tralization. The only neutralizing mAb unable to inhibit
HIV-1–cell binding was the gp41-specific mAb 2F5. We
therefore conclude that the inhibition of virus–cell binding
is a major mechanism of HIV-1 neutralization, and that
mAb 2F5 neutralizes at a stage after virus–cell binding.
 
Materials and Methods
 
Cells and Viruses.
 
The HLA-DR
 
2
 
/CD4
 
1
 
 line A3.01 and its
CD4
 
2
 
 derivative A2.01 were obtained from T. Folks (Center for
Disease Control, Atlanta, GA) and were grown in RPMI 1640
supplemented with 10% FCS (growth medium, GM). The HLA-
DR
 
1
 
/CD4
 
1
 
 PM1 cell line derived from HUT78 by P. Lusso et
al. (38) was obtained from the National Institutes of Health
(NIH) AIDS Research and Reference Reagent Program, Na-
tional Institute of Allergy and Infectious Diseases, NIH, Bethesda,
MD. The HIV-1 molecular clone Hx10 and the TCLA isolate
MN were obtained from A. Fisher (Royal Postgraduate Medical
School Hammersmith Hospital, London, UK; reference 39) and
H. Holmes and the Medical Research Council (MRC) AIDS
Reagent Project, respectively.
 
Antibodies and Recombinant Proteins.
 
The anti-CD4 mouse mAbs
Q4120, Q425, and L120 (from the MRC AIDS Reagent Project)
were previously mapped to the first, third, and fourth domains of
CD4, respectively (40). Q4120 competes with sgp120 for CD4
binding and inhibits HIV infection and syncytium formation,
Q425 inhibits HIV infection and syncytium formation but not
sgp120–cell binding, and L120 does not influence sgp120–cell
binding and only weakly interferes with infection and syncytium
formation (40). Anti-sCD4 sheep antiserum was prepared by
D.M. Konys and M. Page (Biogen, Cambridge, MA) and was ob-
tained from the MRC AIDS Reagent Project. Anti–HLA-DR
mAb L243 was obtained from the American Type Culture Col-
lection (Rockville, MD), DA6 from M. Moore, and BL2 and bi-
otinylated B8.12.2 were from Immunotech SA (Marseille, France).
Rodent anti-gp120-V3 mAbs were from the following sources:
110.5 (41) from Genetic Systems (Seattle, WA) and ICR41 (42)
from J. Cordell (Institute for Cancer Research, Sutton, Surrey,
UK). The human anti–V3 loop mAb 447-52D (43, 44) was pur-
chased from Cellular Products Inc. (Buffalo, NY). The chimpan-
zee anti-gp120-V2 mAb C108G was prepared as previously de-
scribed (45). The human mAbs specific for the CD4bs, 21h, the
CD4-induced epitope (CD4i) 48d (17, 46), and the V3 loop, 19b
(47) were from J. Robinson (University of Connecticut, Storrs,
CT). The anti-CD4bs monospecific antibody IgG1b12 (48), and
its Fab, b12 (49–51), and the anti–V3 loop monospecific antibody
Loop 2, and its Fab, were prepared as previously described (52,
53). The human anti-gp120 mAb 2G12 (18, 19) and the anti-
gp41 mAb 2F5 (54) were prepared by H. Katinger, and were ob-
tained from the MRC AIDS Reagent project. Anti–HIV-1
gp120 antibody D7324, raised against a peptide synthesized from
a highly conserved sequence in the gp120 COOH terminus, was
from Aalto BioReagents Ltd. (Dublin, Ireland). Recombinant
sCD4 was from L. Burkly (Biogen; reference 55). HIV-1 MN
(Baculovirus-produced) was provided by J. Raina and IIIB (Chi-
nese hamster ovary cell–produced)–derived purified recombinant
sgp120s were obtained from the MRC AIDS Reagent Project.
 
Virus Binding and Neutralization Assays.
 
2 
 
3
 
 10
 
7
 
 PM1 cells in- 
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fected overnight with Hx10 or MN at a multiplicity of infection
of 
 
z
 
0.1 were cultured in GM, which was renewed every 24 h to
prevent the accumulation of heat-inactivated virus particles (56)
and to allow culture of the cells at high density. The production
of viral p24 protein was followed by p24 ELISA (57), and the su-
pernatant containing the peak production of p24 was harvested.
The virus supernatant was clarified by centrifugation at 3,000 
 
g
 
,
filtrated through a 0.45 
 
m
 
m filter, and then concentrated by 
 
z
 
10-
fold using a 300-kD cutoff Macrosep centrifugal concentrator
(Filtron Technology Corp., Northborough, MA). The concen-
trated virus was aliquotted and stored at 
 
2
 
80
 
8
 
C until use. Mock-
infected supernatants from uninfected PM1 cells were prepared
and treated in the same way. The virus–cell binding assay was
carried out by incubation of 50 or 100 
 
m
 
l of concentrated virus
(for Hx10 or MN, respectively), or dilutions thereof, at 37
 
8
 
C
with 3 
 
3
 
 10
 
5
 
 A3.01 or A2.01 cells for 30 min unless otherwise
stated, in a total volume of 70 or 120 
 
m
 
l for Hx10 and MN, re-
spectively, unless otherwise stated. Next, the cells were washed
twice in PBS/1% FCS/0.02% sodium azide (wash buffer, WB),
and then resuspended in 50 
 
m
 
l of either a mixture of three non–
cross-competing anti–HLA-DR mAbs, L243, DA6, and BL2 (for
MN and Hx10 virus), or the biotinylated HLA-DR mAb
BL8.12.2 (for Hx10). The mixture of the three anti–HLA-DR
mAbs was used with some virus stocks to increase detection sensi-
tivity, as the signal was too weak when the single biotinylated
mAb was used. After 1 h at 4
 
8
 
C, the cells were washed twice in
WB, and then fixed overnight in 0.2% formaldehyde in WB. No
vortexing was carried out during the washing steps to avoid re-
moving virus bound weakly to the cell surface. After washing
three times in WB, the cells were incubated for 1 h at 4
 
8
 
C in WB
containing either a 1:100 dilution of anti–mouse IgG-phyco-
erythrin or a 1:20 dilution of streptavidin-phycoerythrin (Immu-
notech SA). Bound virus was detected by flow cytometry using a
FACScan
 
Ò
 
 with Lysis II software. Cells gated on side scatter and
forward angle light scatter were analyzed, and each datum point
represents the acquisition of 10,000 gated events. Inhibition by
CD4 mAbs was carried out by preincubating the A3.01 cells for 1 h
at 4
 
8
 
C with different concentrations of mAbs before addition of
virus. Virus neutralization was measured using 5 
 
m
 
l of the same
virus sample used for the binding test, and was carried out as fol-
lows. Serial dilutions made in GM at 4
 
8
 
C (in duplicate) of virus
pretreated or not with anti-Env mAbs was incubated with 3 
 
3
 
10
 
5
 
 A3.01 or C8166 cells for 2 h at 37
 
8
 
C before adding fresh me-
dium. The cells were cultured in 200 
 
m
 
l GM for 10 d, during
which time 100 
 
m
 
l of medium was exchanged for fresh GM every
2 d, and the culture medium monitored for p24 in the superna-
tant by p24 ELISA (57). The viral titer (50% tissue culture infec-
tious dose) was determined as the final dilution (from duplicate
wells by the method of Karber, reference 58) of virus containing
supernatant yielding a positive p24 signal at peak cell-free p24
production, in which the cutoff for p24 positivity was taken as a
signal greater than twice that of the negative control signal. The
binding and neutralization tests were not carried out under iden-
tical conditions, in that the antibody-treated virus was incubated
for 2 h longer with the cells in the neutralization assay than in the
cell binding assay, to allow entry of nonneutralized virus. Results
were analyzed for correlation as follows. The 10-logs of the rela-
tive virus binding and TCID
 
50
 
 values were calculated. Simple re-
gression of the second order of a linear relationship of logTCID
 
50
 
as a function of the log(relative virus binding) was performed as
included in the Statview program (Abacus Concepts, Inc., Berke-
ley, CA). The 
 
P
 
 values were calculated with F and 
 
t
 
 tests.
 
sgp120 Cell Binding Assay.
 
5 
 
3
 
 10
 
5
 
 cells were incubated for
30 min at 37
 
8
 
C with agitation with different concentrations of
sgp120, pretreated or not with mAb, in a total volume of 50 
 
m
 
l in
a 96-well plate. The cells were then washed twice with WB, re-
suspended in 50 
 
m
 
l of 2 
 
m
 
g/ml D7324, and incubated with agita-
tion for 1 h at 4
 
8
 
C. Anti–goat-FITC (Sigma Chemical Co., St.
Louis, MO) was added to the cell pellet at a 1:20 dilution in 50 
 
m
 
l
WB, and then the cells were agitated at 4
 
8
 
C for 1 h and washed
twice in WB. Labeled cells were analyzed by flow cytometry as
described above. For mAb inhibition studies, sgp120 at 10 
 
m
 
g/ml
was preincubated with serial dilutions of anti-gp120 mAbs for 2 h
at 37
 
8
 
C before addition to the target cells as described above.
 
sCD4-infected Cell Binding Assay.
 
The assay was carried out
essentially as previously described (37). In brief, H9 cells were in-
fected with either Hx10 or MN virus at a multiplicity of infection
of 
 
z
 
0.1, and cultured for 8–10 d, respectively, before use. At this
time, the cells were surface CD4
 
2
 
/gp120
 
1
 
 as demonstrated by
mAb staining and flow cytometric analysis. The infected cells
were incubated for 2 h at 37
 
8
 
C in the presence or absence of anti-
HIV mAb at varying dilutions in RPMI/5% FCS, and then biotin-
ylated sCD4 was added to achieve a final concentration of 2 
 
m
 
g/
ml, and incubated for 1 h at 4
 
8
 
C. After washing, the cells were
fixed in 0.2% formaldehyde in WB overnight before washing and
labeling with streptavidin-phycoerythrin (Immunotech SA) at a
1:20 dilution for 1 h at 4
 
8
 
C. After final washes, fluorescence was
analyzed by flow cytometry.
 
Results
 
Detection of Virus–Cell Binding by Anti–HLA-DR Antibodies.
 
The detection of HIV–cell binding by the use of anti–
HIV-specific reagents (anti-gp120 mAbs or anti–HIV-spe-
cific antisera) has two major disadvantages. First, these re-
agents will detect cell-associated sgp120 which has been
shed from the virus before or during the assay, and second,
if the virus has been pretreated with HIV-specific antibod-
ies, these may interfere with binding of the detection anti-
body. To eliminate these potential problems, we took ad-
vantage of the fact that during budding, HIV incorporates
large numbers of HLA-DR molecules into its membrane.
The binding of HLA-DR
 
1
 
 virus particles to CD4
 
1
 
/HLA-
DR
 
2
 
 cells allows detection of bound virions with anti–
HLA-DR mAbs, followed by indirect immunofluorescent
staining and flow cytometric analysis. Binding was carried
out with CD4
 
1
 
/HLA-DR
 
2
 
 A3.01 cells, and the sister cell
line, A2.01 (CD4
 
2
 
/HLA-DR
 
2
 
), was used as a control for
specificity. Moreover, we included mock-infected control
preparations, since cell culture supernatants contain large
numbers of membrane vesicles that carry molecules of cel-
lular origin (59, 60). In preliminary experiments, we incu-
bated concentrated Hx10 or MN virus or mock virus with
A3.01 or A2.01 cells for different times at 37 and 4
 
8
 
C.
Since the binding at 4
 
8
 
C was weak or undetectable and
considered nonphysiological (results not shown), and we
were concerned that incubation periods of 
 
.
 
30 min at
37
 
8
 
C would lead to significant levels of virus–cell mem-
brane fusion which might affect detection of cell-bound,
virion-associated HLA-DR, we selected 30 min at 37
 
8
 
C
for later experiments. The binding of 50 
 
m
 
l of an undiluted
Hx10 preparation (Fig. 1 
 
A
 
) or 100 
 
m
 
l of MN (Fig. 1 
 
B
 
) to
A3.01 and A2.01 cells are represented as flow cytometry 
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histograms. Despite a significant signal obtained on A2.01
cells, which represents CD4-independent binding of virus
and HLA-DR–containing vesicular material, the signal ob-
tained on A3.01 cells was substantially greater with both vi-
ruses, and all of the cells bound virus as demonstrated by
the increased fluorescence of the entire population. The
binding of both Hx10 and MN to A3.01 cells was dose de-
pendent, although nonsaturating under the conditions used
(Fig. 1, 
 
C
 
 and 
 
D
 
), suggesting a low-avidity interaction be-
tween virions and cell-associated CD4. By contrast, the
signal obtained with mock virus on A3.01 cells or virus on
A2.01 cells did not substantially decrease with increasing
dilution of the preparation, suggesting a saturating low
level of CD4-independent binding. Overall, these results
suggest that CD4 is required for efficient virus–cell bind-
ing. To confirm this, we preincubated the A3.01 cells with
CD4 mAbs at a saturating concentration under the experi-
mental conditions used, before addition of virus. The mAb
Q4120, which binds to domain 1 of CD4 and competes for
gp120 binding, inhibited Hx10 virus binding by 95% (Fig.
2). By contrast, neither Q425, which binds to CD4 domain
3 and interferes with HIV–cell fusion but not sgp120–cell
binding, nor L120, which binds CD4 domain 4 and has lit-
tle effect on HIV infection, interfered with HIV-1 binding.
The lack of effect of Q425 on the virion–cell binding signal
implies that HIV–cell fusion has little effect on the assay
readout. Since we were obliged to use a mixture of three
(nonbiotinylated) murine anti–HLA-DR mAbs to detect
MN virus bound to the A3.01 cells to increase sensitivity,
we were unable to carry out inhibition experiments with
antibodies of murine origin. For this reason we used a
polyclonal sheep anti-sCD4 antiserum at a dilution of 1:90,
controlled by normal sheep serum at the same dilution, to
inhibit MN binding. Fig. 2 
 
B
 
 shows that under these con-
ditions, virus binding was completely inhibited by the anti-
serum, whereas the control serum had no obvious effect.
 
sCD4 and CD4bs-specific gp120 mAbs Inhibit HIV–Cell Bind-
ing.
 
The experiments with CD4 mAbs confirmed that
HIV required CD4 on the target cell for specific binding.
We next wished to investigate whether the binding of
ligands to the virus was also able to inhibit HIV–cell bind-
ing in this assay. We initially tested sCD4 for its ability to
interfere with virus binding and to neutralize virus infectiv-
ity, since it has previously been shown to compete with
membrane CD4 for both sgp120 and virion binding. Fig. 3
shows the inhibition of HIV–cell binding and HIV infec-
tivity for Hx10 and MN, respectively. The inhibition of vi-
rus binding paralleled that of neutralization with increasing
sCD4 concentration, suggesting a relationship: an excellent
and highly significant correlation was demonstrated after
analysis of the results, and is summarized in Table 1 (
 
r
 
 
 
5
 
0.96 and 0.93 for Hx10 and MN, respectively). We next
tested a panel of antibodies specific for the CD4 binding
region of gp120 for their ability to neutralize and inhibit
HIV–cell attachment. Fig. 4 shows the effect of Fab b12
and its IgG derivative, IgG1b12, mAb 21h on Hx10–cell
binding and infectivity, and IgG1b12 on MN–cell binding
Figure 1. Binding of HLA-DR1 HIV-1 to HLA-DR2/CD42 and
CD41 cells. Concentrated HIV-1 or mock virus was incubated either un-
diluted or at the dilutions shown for 30 min at 378C with either A3.01 or
A2.01 cells, then cell-bound virus was detected by staining with anti–
HLA-DR mAbs followed by indirect immunofluorescent staining and
analysis by flow cytometry. Each point represents the mean fluorescence
intensity of 10,000 accumulated events transformed into percentage of in-
hibition. A and B show flow cytometry profiles for Hx10 and MN, re-
spectively; the left peak corresponds to the background staining with
anti–HLA-DR mAb alone on A3.01 cells in the absence of virus. C and
D show the concentration dependence of Hx10- and MN-cell binding
respectively as compared to controls.
Figure 2. Inhibition of HIV-cell binding by CD4 mAbs and antisera.
(A) A3.01 cells were preincubated with CD4 mAbs Q4120 (domain 1/
CDR-1/2–like loops), Q425 (domain 3), or L120 (domain 4) at 20 mg/
ml for 2 h at 48C before addition of HIV-1 Hx10. Bound virus was de-
tected as described for Fig. 1. (B) A3.01 cells were preincubated with ei-
ther sCD4-specific sheep antiserum or normal sheep serum at a 1:90 dilu-
tion for 2 h at 48C before addition of HIV-1 MN.1291 Ugolini et al.
and infectivity. The binding of both viruses to A3.01 cells
was strongly inhibited by these anti–CD4 binding site–spe-
cific antibodies. Maximum inhibition of Hx10 binding was
z93, 55, and 86% for IgG1b12, Fab b12 and 21h, respec-
tively, at 200 nM, and maximum inhibition of MN bind-
ing was 89% for IgG1b12 at the same concentration. These
data confirm that a large part of the neutralizing activity of
these antibodies is likely to be competition for virus–CD4
binding. The finding that Fab b12 neutralized and inhibited
virus attachment demonstrates that cross-linking of the viral
glycoproteins is not required for these functions. Further
analysis of the relationship between inhibition of virion–
cell attachment and neutralization for these antibodies re-
vealed a strong to excellent and highly significant correla-
tion for both viruses (Table 1).
Non-CD4bs Neutralizing Antibodies Inhibit HIV–Cell Binding.
Inhibition of HIV-1–cell binding by CD4bs-specific mAbs
was anticipated, since it has previously been shown that
such antibodies are efficient inhibitors of sgp120 binding to
sCD4 and CD41 cells. We next tested neutralizing mAbs
specific for other gp120 epitopes for their ability to inter-
fere with virus–cell binding. Several other confirmed TCLA
virus neutralization epitopes have been identified: the hy-
pervariable V2 and V3 loops, the CD4-induced (CD4i)
epitopes recognized by mAbs 48d and 17b, and the unique
2G12 epitope. Fig. 5 shows the effect of V3 loop–specific
mAbs on virion binding. Unexpectedly, these mAbs inter-
fered with both Hx10– and MN–cell binding; maximum
inhibition of virion attachment at 200 nM by 110.5, ICR41,
and 447-52D was z46, 47, and 85%, respectively, with
Hx10. The effect of V3 loops on MN–cell binding was
more pronounced than on Hx10; 447D, Loop 2, and the
Fab fragment of Loop 2 inhibited MN–cell binding maxi-
mally at 200 nM by 96, 65, and 56%, respectively. Simi-
larly, C108G, 48d, and 2G12 at the same concentration in-
hibited Hx10 binding by 83, 81, and 76%, respectively, and
48d reduced MN attachment by 79% (Fig. 6). Thus, all
anti-gp120 neutralizing mAbs tested were able to interfere
with the binding of two TCLA viruses to a CD41 T cell
line. To determine whether the inhibition of virus-cell
binding was general to all anti–envelope glycoprotein
mAbs, we carried out binding and neutralization analyses
with the neutralizing anti-gp41 mAb 2F5. By contrast with
the results obtained with the anti-gp120 mAbs, 2F5 did not
inhibit HIV–cell binding at any concentration tested, but
potently interfered with HIV infection; at a concentration
of 200 nM, 2F5 reduced Hx10 and MN infectivity by
z80- and 30-fold, respectively (Fig. 6).
The Relationship Between Inhibition of Virus–Cell Binding and
HIV-1 Neutralization. As demonstrated in Figs. 3–6, all
gp120-specific ligands, including sCD4, IgG molecules to
diverse epitopes, and their Fab fragments, inhibited virion
attachment to A3.01 cells. Moreover, analysis of the bind-
ing and neutralization curves revealed that the inhibition of
virion binding correlated with neutralization in all cases (r
.0.5); only the gp41-specific ligand 2F5 showed no corre-
lation (Table 1). However, inspection of the results sum-
marized in Table 1 demonstrates a range in the strength of
the correlations, from excellent and highly significant for
sCD4, IgG1b12, and 48d on Hx10 and Loop 2 on MN, to
correlated but not significant for several others. Although
variability due to imprecision intrinsic to the methods used
prevents any unequivocal interpretation of these differ-
ences, one possibility is that for some ligands, inhibition of
virion attachment to cells may only partially mediate HIV
neutralization, whereas other mechanisms may contribute
to a greater or lesser extent. To analyze this in greater de-
tail, we estimated the percentage of neutralization that is
Figure 3. Inhibition of HIV–cell binding by sCD4. HIV Hx10 (A) or
MN (B) virus was preincubated with increasing concentrations of sCD4
for 2 h at 378C before addition of the A3.01 cells. The virus binding test
was carried out as described for Fig. 1, and data are represented as per-
centage of binding. To measure virus infectivity, serial dilutions of a sam-
ple of the same sCD4-treated virus used for the binding test were incu-
bated with A3.01 cells for 2 h at 378C before culture for 10 d, and the
viral titer calculated at peak p24 production in the culture supernatant.
Neutralization is represented as reduction in infectivity (TCID50).
Figure 4. Inhibition of HIV-1 binding and infectivity by anti-gp120-
CD4bs–specific mAbs. The following antibodies were tested for inhibi-
tion of binding and infectivity of Hx10 virus: (A) mAb IgG1b12; (B) Fab
b12; (C) mAb 21 h. D represents IgG1b12 on MN virus. The experiment
was carried out as described for Fig. 3, and results are represented as per-
centage binding versus reduction in infectivity.1292 Neutralizing Antibody Inhibits HIV-1–cell Binding
the result of inhibition of virus–cell attachment. This analy-
sis was carried out by plotting the relative TCID50 values
(i.e., the postneutralization TCID50 divided by the control
values obtained in the absence of neutralizing ligand) as
function of the percentage of virus binding. The percent-
age of virus binding values were read from fitted linear
curves at half-maximal infectivity; two different values
were obtained for each ligand depending on whether the
Figure 5. Inhibition of HIV-1
binding and infectivity by anti-
gp120-V3 loop–specific mAbs.
The following antibodies were
tested for their ability to inhibit
infectivity and cell binding of
Hx10 virus; (A) 110.5, (B)
ICR41.1, and (C) 447-52D or
MN virus, (D) 447-52D, (E)
Loop 2, and (F) Fab Loop 2. The
experiment was carried out as
described in Fig. 3, and results
are represented as percentage of
binding versus reduction in in-
fectivity.
Table 1. Correlation of Inhibition of HIV-1–cell Attachment and Neutralization
MN Hx10
Specificity Antibody/ligand Correlation Significance
% neutralization
by binding inhibition Correlation Significance
% neutralization
by binding inhibition
r zPr z P
CD4/BS 21h 0.84* 0.02‡ 20–80§ 0.94 0.002 84–88
IgG1b12 0.87 0.01 120 0.99 0.0001 66–90
Fab b12 ND ND ND 0.92 0.004 52–62
sCD4 0.93 0.002 20–120 0.96 0.001 82–100
V3 loop 447-52D 0.74 0.06 80–88 0.83 0.04 82–114
ICR41 NB NB NB 0.63 0.1 70–140
110.5 NB NB NB 0.79 0.04 32–42
Loop 2 0.95 0.001 66–86 NB NB NB
Fab Loop 2 0.83 0.01 88–100 NB NB NB
19b 0.67 0.2 100–116 NB NB NB
Other gp120 2G12 NB NB NB 0.94 0.004 80–128
48d 0.71 0.08 72–100 0.98 0.0002 6–68
C108G NB NB NB 0.83 0.02 78–102
gp41 2F5 0.32 0.5 0 20.25 0.6 0
*Values indicate that the correlation between inhibition of HIV-1 cell binding is excellent (r .0.95); strong (r .0.5); or absent (r ,0.5).
‡,P values estimate significance of correlation between inhibition of HIV–cell binding and neutralization.
§Values represent the percentage of neutralization which is the result of the inhibition of virus–cell attachment. The range represents reading within
a linear curve at two points; half the value for 0 ligand and half the value where 100% mean fluorescent intensity intersects the linear curve.
iNB indicates no detectable mAb binding to virus and no detectable neutralization.1293 Ugolini et al.
curves were read at 50% of the infectivity for 0 ligand or at
50% of the infectivity corresponding to 100% virus bind-
ing. These two readings represent a range of uncertainty in
the estimates. Thus, the approximate fraction of virus that
was prevented by ligand from binding to the cells at 50%
neutralization could be calculated. If it is granted that virus
that has not bound cannot infect, the unbound virus would
correspond to the minimal fraction of the neutralization
that was attributable to block of virus attachment. How-
ever, it should be noted that for the percentage of neutral-
ization to be considered as due to a block of virus binding,
it is assumed that the relationship between the mean fluo-
rescence intensity values for bound virus and the numbers
of infectious virions bound is linear in the relevant zone.
The values presented in Table 1 indicate that for many of
the ligands (21h, 447-52D, 2G12, and sCD4 for Hx10 and
IgG1b12, Fab Loop 2, 447-52D, and 19b for MN) the
likely contribution of inhibition of attachment to neutral-
ization was .80%, suggesting that this is probably the
dominant mechanism of neutralization. For others, the
range was greater but did not exclude the possibility of a
major role for inhibition of attachment in neutralization.
Of the gp120-specific ligands, only 110.5 binding to Hx10
suggested a relatively minor role of inhibition of binding in
neutralization, and the gp41-specific mAb 2F5 clearly neu-
tralized both viruses by a mechanism unrelated to interfer-
ence with HIV–cell attachment.
Inhibition of sgp120 to CD41 Cells and sCD4 to HIV-infected
Cells. Previous studies have shown that V3 loop–specific
mAbs are unable to inhibit sgp120 binding to CD41 cells.
To confirm this, and to investigate the effects of other,
non-CD4bs mAbs on sgp120–cell binding, we measured
the association of antibody-pretreated sgp120 with A3.01
cells. The results are summarized in Table 2; all CB4bs an-
tibodies and sCD4 inhibited both IIIB and MN sgp120–
cell binding by 50% at concentrations ranging from 0.06
nM (IgG1b12 on MN) to 120 nM (Fab b12 on Hx10). By
contrast, only three non-CD4bs mAbs achieved 50% inhi-
bition of sgp120–cell binding; the anti–V3 loop mAbs
ICR41 and Loop 2 on Hx10 and MN, respectively, and the
CD4i-epitope specific mAb 48d with both viruses. Thus,
the inhibition by neutralizing antibodies of sgp120 binding
to CD41 cells is not representative of the inhibition of vi-
rus binding to the same cells. Since gp120 is in an oligo-
meric, gp41-associated form on the surface of infectious
virions, it seemed important to investigate the effect of the
neutralizing antibodies on the interaction between CD4
and virion-associated envelope glycoprotein. We therefore
analyzed the ability of anti-gp120 neutralizing antibodies to
inhibit the association of biotinylated sCD4 with HIV-
infected (Hx10 or MN) cells. Similar to the results obtained
for sgp120 binding to CD41 cells, the CD4bs-specific IgG
molecules and sCD4 inhibited the sCD4-oligomeric gp120
interaction by 50% within a range of 0.7–6 nM, and the
Fab b12 at 10–100 nM (Table 2). Thus, these ligands in-
hibit the gp120-CD4 interaction in all assays tested. How-
ever, in complete contrast to the virus–cell binding assay,
antibodies to epitopes other than the CD4bs showed little
or no inhibition of sCD4 binding to HIV-infected cells
(Table 2); none of the antibodies achieved 50% inhibition
at the highest dose tested (200 nM).
Discussion
We show here that mAbs to all confirmed HIV-1 gp120
neutralizing epitopes inhibit the binding of two TCLA vi-
ruses, one a molecular clone, the other a nonclonal isolate,
to a CD41 T cell line, and that in all cases inhibition of vir-
ion attachment correlated with neutralization. These data
strongly support the idea that inhibition of HIV–cell at-
tachment is a major mechanism of TCLA HIV-1 neutral-
ization. Thus, we confirm previous reports that mAbs specific
for the gp120 CD4bs are potent inhibitors of sgp120–cell
and virion–cell binding (7–11), but also demonstrate un-
equivocally that mAbs that react with the V2 and V3 loops
and other independent structures (CD4i and 2G12
epitopes) also interfere with virus–cell binding. We have
demonstrated this by the use of a novel virus–cell attach-
ment assay based on the detection, with anti–HLA-DR an-
tibodies, of HLA-DR1 virus binding to CD41/HLA-DR2
cells. In this way we have eliminated two potential artefacts
of previously described HIV–cell binding assays that at-
tempted to detect cell-bound virus using envelope glyco-
Figure 6. Inhibition of HIV-1 binding and infectivity by mAbs to
other, non-CD4bs epitopes. The following antibodies were tested for
their ability to inhibit infectivity and cell binding of Hx10 virus; (A) 48d,
(B) 2G12, (C) anti-gp41 2F5, (D) C108G or MN virus, (E) 48d, and (F)
2F5. The experiment was carried out as described in Fig. 3, and results are
represented as percentage of binding versus reduction in infectivity.1294 Neutralizing Antibody Inhibits HIV-1–cell Binding
protein–specific antibodies: (a) the contamination of the vi-
rus–cell binding signal by shed sgp120 bound to cellular
CD4, and (b) interference with detection of the bound vi-
rus by ligands prebound to the virus envelope glycopro-
teins.
The ability of neutralizing mAbs other than those spe-
cific for the gp120 CD4bs to inhibit virion–cell and, in
some cases, sgp120 cell binding suggests that a mechanism
other than direct competition for attachment to membrane
CD4 is functioning. It may be that non-CD4bs mAbs in-
terfere sterically with the gp120-CD4 interaction, particu-
larly in the case where the gp120 molecules are tightly
packed into a gp41-associated oligomer. Although we can-
not rule this out as the mechanism of inhibition, the lack of
interference of sCD4 binding to oligomeric gp120 on
HIV-infected cells by non-CD4bs mAbs suggests that this
explanation may not be sufficient. Moreover, the Fab frag-
ment of the V3-specific mAb Loop2 interfered efficiently
with MN virion–cell binding, further suggesting that steric
considerations are unlikely to be dominant. Another possi-
bility is that the binding of ligands to regions outside of the
gp120 CD4bs induces conformational changes in the CD4
binding site, reducing its affinity for CD4. It is well estab-
lished that the binding of sCD4 to virus or virus-infected
cells can induce conformational changes in gp120 leading to
increased exposure of spatially distinct epitopes such as the
V3 loop (37, 61), and mAbs to epitopes including the
CD4bs and the V2 and V3 loops have been reported to
neutralize synergistically (11, 42, 62–66). However, the in-
ability of most non-CD4bs–specific ligands to interfere in
either sgp120 binding to CD41 cells, or sCD4 binding to
oligomeric gp120, again argues against this being the sole
explanation. An additional factor which will influence
HIV–cell binding is the number of intact envelope glyco-
protein spikes per virion (67). Thus, mAbs which induce
the dissociation of a critical number of gp120 molecules
from gp41 will reduce virus–cell binding. This may be a
factor in the reduction of Hx10-A3.01 binding, since 48d
and V3 loop mAbs, such as 110.5 used in this study, have
been shown to induce substantial gp120 dissociation (27).
However, MN virus is much less sensitive to mAb-induced
gp120 dissociation than Hx10, and sCD4 and 48d are the
only ligands tested in this study that induce detectable loss of
gp120 from the virion (results not shown). Moreover, if
mAb-induced gp120 shedding was a major factor impli-
cated in the reduction of HIV–cell binding, mAbs such as
110.5 and 48d would be expected to substantially inhibit
sCD4 binding to virus-infected cells, which is not the case.
An intriguing possibility is that for HIV–cell binding of
adequate avidity to allow virus–cell fusion, the virus may
need to occupy binding sites on both CD4 and the appro-
priate coreceptor molecule. In this model, HIV may bind
initially with relatively weak avidity to CD4, then rapidly
recruit coreceptor molecules into the complex, or may
bind only with sufficient avidity to remain attached to the
cell if CD4 and the coreceptor are already established in a
preformed complex. Thus, although the avidity of the
HIV-1–CD41 cell interaction has never been directly de-
termined, measurement of virion–sCD4 binding suggests
that it is likely to be substantially lower than that obtained
for sgp120–CD4 (35, 36). In accord with this idea, analyses
of virion adsorption to CD41 cells strongly suggests that
Table 2. Inhibition of Virus and sgp120 Binding to CD41 Cells, and sCD4 Binding to HIV1 Cells
Hx10 MN
Specificity Antibody/ligand Virion sgp120 sCD4 Virion sgp120 sCD4
CD4/BS IgG1b12 3.0* 20‡ 6.0§ 0.06 4.0 1.5
Fab b12 120 30 10 ND 2.0 100
21h 20 15 ND ND 8.0 ND
sCD4 6.0 15 0.7 2.0 2.0 0.7
V3 ICR41 200 200 .200 NBi NB NB
447-52D 0.4 .200 .200 0.7 .200 .200
Loop 2 NB NB NB 4.0 30 .200
Fab Loop 2 NB NB NB 200 .700 .200
19b NB NB NB 0.4 .200 .200
V2 C108G 0.8 ND ND NB NB NB
Other gp120 48d 7.0 30 .200 20 7.0 .200
2G12 2.0 .200 .200 NB .200 .200
gp41 2F5 .200 .200 .200 .200 .200 .200
*Represents concentration (nM) required for 50% inhibition of virus–A3.01 cell binding.
‡Represents concentration (nM) required for 50% inhibition of sgp120–A3.01 cell binding.
§Represents concentration (nM) required for 50% inhibition of sCD4–infected cell binding.
iNB represents no detectable mAb binding to virus and no neutralization; absence of epitope or no epitope accessibility on the virion.1295 Ugolini et al.
this is an inefficient process (68), and a requirement for
coreceptor molecules in the virus–cell attachment process
has been postulated (69). Additionally, the finding that
sCD4 triggers the exposure on gp120 of a binding site for
CCR5 (29) suggests that this may be the sequence of
events followed during virus–cell binding, and is consistent
with the notion of two-site receptor binding. Moreover, it
has been demonstrated that neutralizing mAbs to gp120
epitopes outside of the CD4bs inhibit the gp120–CCR5
interaction (28, 29), reinforcing the idea that for a success-
ful entry into the target cell, gp120 binding to both recep-
tor molecules is probably required.
Our results do not exclude the possibility that some of
the mAbs tested also neutralize by mechanisms other than
inhibition of virion–cell attachment; antibody-complexed
virus escaping the block to attachment may nevertheless be
neutralized at later steps in the life cycle. In this respect, the
inhibition of virion–cell attachment may be considered as
the most extreme end point resulting from a block to a
critical number of virus–receptor interactions. The inhibi-
tion of a smaller number of virus–receptor interactions may
not be sufficient to prevent virion attachment, but may in-
hibit the fusion process. Thus, for many of the antibodies
tested here, inhibition of virus–receptor binding may be
the dominant mechanism of neutralization, resulting in a
block to virus–cell fusion, although only partial inhibition
of attachment is observed. In another scenario, V3 loop–
specific mAbs have been shown to neutralize cell-attached
virus (24–26), and have been postulated to inhibit fusion or
postfusion steps in the HIV-1 life cycle (26), and certain
anti-CD4bs antibodies have been suggested to inhibit both
HIV–cell membrane fusion and a postfusion step (70).
However, alternative explanations for postattachment neu-
tralization are that such mAbs either prevent the formation
of a sufficient number of virus–receptor interactions to ini-
tiate fusion, or simply dissociate weakly adsorbed virus by
interfering with a reversible binding step. These explana-
tions seem reasonable if one considers that viral entry into
certain CD41 T cell lines such as A3.01 is in the order of
several h, as has been observed previously (71).
The data presented here are not consistent with recent
studies that failed to demonstrate inhibition of HIV–cell
binding with either sCD4 (72, 73) or the CD4bs-specific
Fab b12 or its IgG derivative, IgG1b12 (70). The reasons
for this are unclear. Demaria and co-workers (72, 73) de-
tected virus binding using an anti–gp120-specific antise-
rum; pretreatment of virions with sCD4 or mAbs is there-
fore likely to modify the subsequent detection of bound
virus. We have eliminated this possibility in our study by
detecting bound virions using mAbs to a cell-derived mol-
ecule. We carried out the virus–cell binding at 378C,
whereas Demaria and co-workers (72, 73) and McInerney
et al. (70) use 48C for most experiments. However, this is
unlikely to explain the differences observed, since McIner-
ney et al. failed to find significant changes when their assay
was run at either 4 or 378C, and we find that both IgG1b12
and Fab b12 inhibit HIV–cell binding when carried out at
48C (results not shown). We chose to carry out our virus–
cell binding assay at 378C as these conditions were most
likely to represent the physiological conditions encoun-
tered by the virus during binding to its target cell. Virus–
cell binding is temperature dependent, as has been shown
in previous studies (35, 36) and it is clear from our own
analyses that HIV–cell binding is much reduced at 48C (re-
sults not shown). Although there was a risk that a small
amount of virus–cell fusion might occur in our assay, it
seems unlikely that this would strongly influence the re-
sults, since (a) fusion appears to be a relatively slow process,
and 50% entry of a TCLA virus into A3.01 cells was shown
to take 4 h (71), and (b) fused virus would probably leave
an HLA-DR footprint at the cell surface which would be
detected by antibody. Moreover, we found that pretreat-
ment of the A3.01 cells with Q425, a CD4 mAb that in-
hibits HIV–cell fusion but not virus–cell binding, did not
significantly modify the signal corresponding to bound vi-
rus, again implying that fusion is unlikely to alter the readout.
The studies we have described here have all been carried
out using two TCLA viruses; it will now be important to
determine whether cell attachment by primary isolates, par-
ticularly those using predominantly the CCR5 coreceptor,
is also inhibited by anti–gp120-specific mAbs. Such experi-
ments are not easy since the relatively high concentration
of virus particles required to carry out the virus–cell bind-
ing assay described here is difficult to obtain for PBL or
macrophage-grown viruses. However, in the absence of
these data it seems reasonable to assume that since all HIV-1
viruses probably use a fundamentally conserved mechanism
of binding and fusion, the inhibition of virus–cell binding is
an important mechanism of antibody-mediated neutraliza-
tion which requires further investigation using primary vi-
ruses.
We wish to thank J.P. Moore for helpful discussion concerning this study; J. Robinson for human mAbs
21h, 19b and 48d; and L. Burkly for sCD4.
This work was supported by the Centre National de la Recherche Scientifique, the Institut National de la
Santé et la Recherche Médicale, the Agence Nationale de Recherches sur le SIDA, and by the EC Con-
certed Action Programmes “HIV variability” and “Antibody mediated enhancement and neutralization of
lentivirus infections: role in immune pathogenesis and vaccine development”.1296 Neutralizing Antibody Inhibits HIV-1–cell Binding
References
1. Dimmock, N.J. 1993. Neutralization of animal viruses. Curr.
Top. Microbiol. Immunol. 183:1–149.
2. Dimmock, N.J. 1995. Update on the neutralization of animal
viruses. Rev. Med. Virol. 5:165–179.
3. Iorio, R.M., R.L. Glickman, A.M. Riel, J.P. Sheenan, and
M.A. Bratt. 1989. Functional and neutralization profile of
seven overlapping antigenic sites on the HN glycoprotein of
Newcastle disease virus: monoclonal antibodies to some sites
prevent attachment. Virus Res. 13:245–262.
4. Smith, T.J., N.H. Olson, R.H. Cheng, H. Liu, E.S. Chase,
W.M. Lee, D. Leippe, A.G. Mosser, R.R. Rueckert, and
T.S. Baker. 1993. Structure of human rhinovirus complexed
with Fab fragments from a neutralizing antibody. J. Virol. 67:
1148–1158.
5. Massey, R.J., and G. Schoetman. 1981. Topographical analy-
sis of viral epitopes using monoclonal antibodies: mechanism
of virus neutralization. Virology. 115:20–32.
6. Kennedy-Stoskopf, S., and O. Narayan. 1986. Neutralizing
antibodies to visna lentivirus: mechanism of action and possi-
ble role in virus persistence. J. Virol. 59:37–44.
7. McDougal, J.S., J.K.A. Nicholson, G.D. Cross, S.P. Cort,
M.S. Kennedy, and A.C. Mawle. 1986. Binding of the hu-
man retrovirus HTLV-III/LAV/ARV/HIV to the CD4 (T4)
molecule: conformational dependence, epitope mapping, an-
tibody inhibition, and potential for idiotypic mimicry. J. Im-
munol. 137:2937–2944.
8. Sun, N.-C., D.D. Ho, C.R.Y. Sun, R.-S. Liou, W. Gordon,
M.S.C. Fung, X.-L. Li, R.C. Ting, T.H. Lee, N.T. Chang,
and T.-W. Chang. 1989. Generation and characterization of
monoclonal antibodies to the putative CD4-binding domain
of human immunodeficiency virus type 1 gp120. J. Virol. 63:
3579–3585.
9. Ho, D.D., J.C. Kaplan, I.E. Rackauskas, and M.E. Gurney.
1988. Second conserved domain of gp120 is important for
HIV infectivity and antibody neutralization. Science (Wash.
DC). 239:1021–1023.
10. Posner, M.R., T. Hideshima, T. Cannon, M. Mukherjee,
K.H. Mayer, and R.A. Byrn. 1991. An IgG human mono-
clonal antibody that reacts with HIV-1 gp120, inhibits virus
binding to cells, and neutralizes infection. J. Immunol. 146:
4325–4332.
11. Montefiori, D.C., B.S. Graham, J. Zhou, J. Zhou, R.A.
Bucco, D.H. Schwartz, L.A. Cavacini, M.R. Posner, and the
NIH-NIAID AIDS Vaccine Clinical Trials Network. 1993.
V3-specific neutralizing antibodies in sera from HIV-1 gp160-
immunized volunteers block fusion and act synergistically with
human monoclonal antibody to the conformation-dependent
CD4 binding site. J. Clin. Invest. 92:840–847.
12. Moore, J.P., and D.D. Ho. 1995. HIV neutralization: the
consequence of viral adaptation to growth on transformed T
cells. AIDS (Lond.). 9(Suppl. A):S117–S136.
13. Poignard, P., P.J. Klasse, and Q.J. Sattentau. 1996. Neutral-
ization of the human immunodeficiency virus type 1. Immu-
nol. Today. 17:239–246.
14. Sattentau, Q.J. 1996. Neutralization of HIV by antibody.
Curr. Opin. Immunol. 8:540–545.
15. Burton, D.R., and D.C. Montefiori. 1997. The antibody re-
sponse in HIV-1 infection. AIDS (Lond.). 11(Suppl. A):S87–
S98.
16. Chamat, S., P. Nara, L. Berquist, A. Whalley, W.J. Morrow,
H. Kohler, and C.Y. Kang. 1992. Two major groups of neu-
tralizing anti-gp120 antibodies exist in HIV-infected individ-
uals. Evidence for epitope diversity around the CD4 attach-
ment site. J. Immunol. 149:649–654.
17. Wyatt, R., J. Moore, M. Accola, E. Desjardin, J. Robinson,
and J. Sodroski. 1995. Involvement of the V1/V2 variable
loop structure in the exposure of human immunodeficiency
virus type 1 gp120 epitopes induced by receptor binding. J.
Virol. 69:5723–5733.
18. Trkola, A., A.B. Pomales, H. Yuan, B. Korber, P.J. Maddon,
G.P. Allaway, H. Katinger, C.F. Barbas III, D. Burton, D.D.
Ho, and J.P. Moore. 1995. Cross-clade neutralization of pri-
mary isolates of human immunodeficiency virus type 1 by
human monoclonal antibodies and tetrameric CD4-IgG. J.
Virol. 69:6609–6617.
19. Trkola, A., M. Purtscher, T. Muster, C. Ballaun, A. Buch-
acher, N. Sullivan, K. Srinivasan, J. Sodroski, J. Moore, and
H. Katinger. 1996. Human monoclonal antibody 2G12 de-
fines a distinctive neutralization epitope on the gp120 glyco-
protein of human immunodeficiency virus type 1. J. Virol.
70:1100–1108.
20. Moore, J.P., and J. Sodroski. 1996. Antibody cross competi-
tion analysis of the human immunodeficiency virus type 1
gp120 exterior envelope glycoprotein. J. Virol. 70:1863–
1872.
21. Linsley, P.S., J.A. Ledbetter, E. Kinney-Thomas, and S.-L.
Hu. 1988. Effects of anti-gp120 monoclonal antibodies on
CD4 receptor binding by the env protein of human immu-
nodeficiency virus type 1. J. Virol. 62:3695–3702.
22. Bahraoui, E., B. Clerget-Raslain, F. Chapuis, R. Olivier, C.
Parravicini, M. Yagello, L. Montagnier, and J.-C. Gluckman.
1988. A molecular mechanism of inhibiton of HIV-1 binding
to CD41 cells by monoclonal antibodies to gp110. AIDS
(Lond.).  2:165–169.
23. Skinner, M.A., A.J. Langlois, C.B. McDanal, J.S. McDougal,
D.P. Bolognesi, and T.J. Matthews. 1988. Neutralizing anti-
bodies to an immunodominant envelope sequence do not
prevent gp120 binding to CD4. J. Virol. 62:4195–4200.
24. Lu, S., S.D. Putney, and H.L. Robinson. 1992. Human im-
munodeficiency virus type 1 entry into T cells: more-rapid
escape from an anti–V3 loop than from an antireceptor anti-
body. J. Virol. 66:2457–2550.
25. Pelchen-Matthews, A., P. Clapham, and M. Marsh. 1995.
Role of CD4 endocytosis in human immunodeficiency virus
infection. J. Virol. 69:8164–8168.
26. Armstrong, S.J., T.L. McInerney, L. McLain, B. Wahren, J.
Hinkula, M. Levi, and N.J. Dimmock. 1996. Two neutraliz-
ing anti-V3 monoclonal antibodies act by affecting different
functions of human immunodeficiency virus type 1. J. Gen.
Virol. 77:2931–2941.
Address correspondence to Dr. Q.J. Sattentau, Centre d’Immunologie de Marseille Luminy, 163 Avenue de
Luminy, Case 906, 13288 Marseille Cedex 9, France. Phone: 33-4-91-26-94-94; FAX: 33-4-91-26-94-30;
E-mail: sattenta@ciml.univ-mrs.fr
Received for publication 25 June 1997 and in revised form 13 August 1997.1297 Ugolini et al.
27. Poignard, P., T. Fouts, D. Naniche, J.P. Moore, and Q.J.
Sattentau. 1996. Neutralizing antibodies to human immuno-
deficiency virus type–1 gp120 induce envelope glycoprotein
subunit dissociation. J. Exp. Med. 183:473–484.
28. Trkola, A., T. Dragic, J. Arthos, J.M. Binley, W.C. Olson,
G.P. Allaway, C. Cheng-Mayer, J. Robinson, P.J. Maddon,
and J.P. Moore. 1996. CD4-dependent, antibody sensitive
interactions between HIV-1 and its co-receptor CCR-5. Na-
ture (Lond.). 384:184–187.
29. Wu, L., N.P. Gerard, R. Wyatt, H. Choe, C. Parolin, N.
Ruffing, A. Borsetti, A.A. Cardoso, E. Desjardin, W. New-
man, et al. 1996. CD4-induced interaction of primary HIV-1
gp120 glycoproteins with the chemokine receptor CCR-5.
Nature (Lond.). 384:179–183.
30. Tilley, S.A., W.J. Honnen, M.E. Racho, M. Hilgartner, and
A. Pinter. 1991. A human monoclonal antibody against the
CD4-binding site of HIV-1 gp120 exhibits potent, broadly
neutralizing activity. Res. Virol. 142:247–259.
31. Thali, M., U. Olshevsky, C. Furman, D. Gabuzda, M. Pos-
ner, and J. Sodroski. 1991. Characterization of a discontinu-
ous human immunodeficiency virus type 1 gp120 epitope
recognised by a broadly reactive neutralising human mono-
clonal antibody. J. Virol. 65:6188–6193.
32. Earl, P.L., C.C. Broder, D. Long, S.A. Lee, J. Peterson, S.
Chakrabarti, R.W. Doms, and B. Moss. 1994. Native oligo-
meric human immunodeficiency virus type 1 envelope gly-
coprotein elicits diverse monoclonal antibody reactivities. J.
Virol. 68:3015–3026.
33. Bou-Habib, D.C., G. Roderiquez, T. Oravecz, P.W. Ber-
man, P. Lusso, and M.A. Norcross. 1994. Cryptic nature of
envelope V3 region epitopes protects primary monocytotro-
pic human immunodeficiency virus type 1 from antibody
neutralization.  J. Virol. 68:6006–6013.
34. Sattentau, Q.J., and J.P. Moore. 1995. Human immunodefi-
ciency virus type 1 neutralization is determined by epitope
exposure on the gp120 oligomer. J. Exp. Med. 182:185–196.
35. Moore, J.P., J.A. McKeating, W.A. Norton, and Q.J. Satten-
tau. 1991. Direct measurement of soluble CD4 binding to
human immunodeficiency virus type 1 virions: gp120 disso-
ciation and its implications for virus-cell binding and fusion
reactions and their neutralization by soluble CD4. J. Virol.
65:1133–1140.
36. Moore, J.P., J.A. McKeating, Y. Huang, A. Ashkenazi, and
D.D. Ho. 1992. Virions of primary human immunodefi-
ciency virus type 1 isolates resistant to soluble CD4 (sCD4)
neutralisation differ in sCD4 binding and glycoprotein gp120
retention from sCD4-sensitive isolates. J. Virol. 66:235–243.
37. Sattentau, Q.J., J.P. Moore, F. Vignaux, F. Traincard, and P.
Poignard. 1993. Conformational changes induced in the en-
velope glycoproteins of the human and simian immunodefi-
ciency viruses by soluble receptor binding. J. Virol. 67:7383–
7393.
38. Lusso, P., F. Cocchi, C. Balotta, P.D. Markham, A. Louie, P.
Farci, R. Pal, R.C. Gallo, and J.M.C. Reitz. 1995. Growth
of macrophage-tropic and primary human immunodeficiency
virus type 1 (HIV-1) isolates in a unique CD41 T cell clone
(PM1): failure to downregulate CD4 and to interfere with
cell line–tropic HIV-1. J. Virol. 69:3712–3720.
39. Fisher, A.G., B. Ensoli, D. Looney, A. Rose, R.C. Gallo,
M.S. Saag, G.M. Shaw, B.H. Hahn, and F. Wong-Staal.
1988. Biologically diverse molecular variants within a single
HIV-1 isolate. Nature (Lond.). 334:444–447.
40. Healey, D., L. Dianda, J.P. Moore, J.S. McDougal, M.J.
Moore, P. Estess, D. Buck, P.D. Kwong, P.C.L. Beverley,
and Q.J. Sattentau. 1990. Novel anti-CD4 monoclonal anti-
bodies separate human immunodeficiency virus infection and
fusion of CD41 cells from virus binding. J. Exp. Med. 172:
1233–1242.
41. Kinley-Thomas, E., J.N. Weber, J. McClure, P.R. Clapham,
M.C. Singhal, M.K. Shriver, and R.A. Weiss. 1988. Neutral-
izing monoclonal antibodies to the AIDS virus. AIDS
(Lond.).  2:25–29.
42. McKeating, J.A., J. Cordell, C.J. Dean, and P. Balfe. 1992.
Synergistic interaction between ligands binding to the CD4
binding site and V3 domain of human immunodeficiency vi-
rus type I gp120. Virology. 191:732–742.
43. Gorny, M.K., S. Conley, A. Karwowska, A. Buchbinder, J.-Y.
Xu, E.A. Emini, S. Koenig, and S. Zolla-Pazner. 1992. Neu-
tralization of diverse human immunodeficiency virus type 1
variants by an anti-V3 human monoclonal antibody. J. Virol.
66:7538–7542.
44. Conley, A.J., M.K. Gorny, J.A. Kessler, L.J. Boots, M. Osso-
rio-Castro, S. Koenig, D.W. Lineberger, E.A. Emini, C.
Williams, and S. Zolla-Pazner. 1994. Neutralization of pri-
mary human immunodeficiency virus type 1 isolates by the
broadly reactive anti-V3 monoclonal antibody, 447-52D. J.
Virol. 68:6994–7000.
45. Warrier, S.V., A. Pinter, W.J. Honnen, M. Girard, E. Much-
more, and S.A. Tilley. 1994. A novel, glycan-dependent
epitope in the V2 domain of human immunodeficiency virus
type 1 gp120 is recognised by a highly potent, neutralizing
chimpanzee monoclonal antibody. J. Virol. 68:4636–4642.
46. Thali, M., J.P. Moore, C. Furman, M. Charles, D.D. Ho, J.
Robinson, and J. Sodroski. 1993. Characterization of con-
served human immunodeficiency virus type 1 gp120 neutral-
ization epitopes exposed upon gp120-CD4 binding. J. Virol.
67:3978–3988.
47. Moore, J.P., A. Trkola, B. Korber, L.J. Boots, J.A. Kessler,
F.E. McCutchan, J. Mascola, D.D. Ho, J. Robinson, and A.J.
Conley. 1995. A human monoclonal antibody to a complex
epitope in the V3 region of gp120 of human immunodefi-
ciency virus type 1 has broad reactivity within and outside
clade B. J. Virol. 69:122–130.
48. Burton, D.R., J. Pyati, R. Koduri, S.J. Sharp, G.B. Thorn-
ton, P.W. Parren, L.S. Sawyer, R.M. Hendry, N. Dunlop,
P.L. Nara, and D. Burton. 1994. Efficient neutralization of
primary isolates of HIV-1 by a recombinant human mono-
clonal antibody. Science (Wash. DC). 266:1024–1027.
49. Burton, D.R., C.F.I. Barbas, M.A.A. Persson, S. Koenig,
R.M. Chanock, and R.A. Lerner. 1991. A large array of hu-
man monoclonal antibodies to HIV-1 from combinatorial li-
braries of asymptomatic seropositive individuals. Proc. Natl.
Acad. Sci. USA. 88:10134–10137.
50. Barbas, C.F.I., E. Bjorling, F. Chiodi, F. Dunlop, D. Cababa,
T.M. Jones, S.L. Zebedee, M.A.A. Persson, P.L. Nara, E.
Norrby, and D. Burton. 1992. Recombinant human Fab
fragments neutralize human type 1 immunodeficiency virus
in vitro. Proc. Natl. Acad. Sci. USA. 89:9339–9343.
51. Roben, P., J.P. Moore, M. Thali, J. Sodroski, C.F. Barbas
III, and D. Burton. 1994. Recognition properties of a panel
of human recombinant Fab fragments to the CD4 binding
site of gp120 that show differing abilities to neutralize human
immunodeficiency virus type 1. J. Virol. 68:4821-4828.
52. Barbas, C.F.I., T.A. Collett, W. Amberg, P. Roben, J. Bin-
ley, D. Hoekstra, D. Cababa, T.M. Jones, R.A. Williamson,
G.R. Pilkington, et al. 1993. Molecular profile of an anti-1298 Neutralizing Antibody Inhibits HIV-1–cell Binding
body response to HIV-1 as probed by combinatorial libraries.
J. Mol. Biol. 230:812–823.
53. Ditzel, H.J., P.W.H.I. Parren, J. Binley, J. Sodroski, J.P.
Moore, C.F. Barbas, and D.R. Burton. 1997. Mapping the
protein surface of HIV-1 gp120 using human monoclonal
antibodies from phage display libraries. J. Mol. Biol. 267:684–
689.
54. Muster, T., F. Steindl, M. Purtscher, A. Trkola, A. Klima, G.
Himmler, F. Ruker, and H. Katinger. 1993. A conserved
neutralizing epitope on gp41 of human immunodeficiency
virus type 1. J. Virol. 67:6642–6647.
55. Fisher, R.A., J.M. Bertonis, W. Meier, V.A. Johnson, D.S.
Costopoulos, T. Liu, R. Tizard, B.D. Walker, M.S. Hirsch,
R.T. Schooley, et al. 1988. HIV infection is blocked in vitro
by recombinant soluble CD4. Nature (Lond.). 331:76–78.
56. McKeating, J.A., A. McKnight, and J.P. Moore. 1991. Dif-
ferential loss of envelope glycoprotein gp120 from virions of
human immunodeficiency virus type 1 isolates: effects on in-
fectivity and neutralisation. J. Virol. 65:852–860.
57. Moore, J.P., J.A. McKeating, R.A. Weiss, and Q.J. Sattentau.
1990. Dissociation of gp120 from HIV-1 virions induced by
soluble CD4. Science (Wash. DC). 250:1139–1142.
58. Karber, G. 1931. Beitrag zur kollectiven Behandlung phar-
macologoscher Reihenversuche. Arch. Exp. Pathol. Pharma-
kol. 162:480–487.
59. Gluschankof, P., I. Mondor, H.R. Gelderblom, and Q.J. Sat-
tentau. 1997. Cell membrane vesicles are a major contami-
nant of gradient-enriched human immunodeficiency virus
type 1 (HIV-1) preparations. Virology. 230:125–133.
60. Bess, J.W., R.J. Gorelick, L.E. Henderson, and L.O. Arthur.
1997. Microvesicles are a source of contaminating cellular
proteins found in purified HIV-1 preparations. Virology. 230:
134–144.
61. Sattentau, Q.J., and J.P. Moore. 1991. Conformational changes
induced in the human immunodeficiency virus envelope gly-
coproteins by soluble CD4 binding. J. Exp. Med. 174:407–
415.
62. Kennedy, M.S., S. Orloff, C.C. Ibegbu, C.D. Odell, P.J.
Maddon, and J.S. McDougal. 1991. Analysis of synergism/
antagonism between HIV-1 antibody-positive human sera
and soluble CD4 in blocking HIV-1 binding and infectivity.
AIDS Res. Hum. Retroviruses. 7:975–981.
63. Tilley, S.A., W.J. Honnen, M.E. Racho, T.-C. Chou, and A.
Pinter. 1992. Synergistic neutralization of HIV-1 by human
monoclonal antibodies against the V3 loop and the CD4-
binding site of gp120. AIDS Res. Hum. Retroviruses. 8:461–
467.
64. Potts, B.J., K.G. Field, Y. Wu, M. Posner, L. Cavacini, and
M. White-Scharfe. 1993. Synergistic inhibition of HIV-1 by
CD4 binding domain reagents and V3-directed monoclonal
antibodies. Virology. 197:415–419.
65. Laal, S., S. Burda, M.K. Gorny, S. Karwowska, A. Buch-
binder, and S. Zolla-Pazner. 1994. Synergistic neutralization
of human immunodeficiency virus type 1 by combinations of
human monoclonal antibodies. J. Virol. 68:4001–4008.
66. Vijh-Warrier, S., A. Pinter, W.J. Honnen, and S.A. Tilley.
1996. Synergistic neutralization of human immunodeficiency
virus type 1 by a chimpanzee monoclonal antibody against
the V2 domain of gp120 in combination with monoclonal
antibodies against the V3 loop and the CD4 binding site. J.
Virol. 70:4466–4473.
67. Klasse, P.J., and J.P. Moore. 1996. Quantitative model of an-
tibody- and soluble CD4–mediated neutralization of primary
isolates and T cell line–adapted strains of human immunode-
ficiency virus type 1. J. Virol. 70:3668–3677.
68. Kabat, D., S.L. Kozak, K. Wehrly, and B. Chesebro. 1994.
Differences in CD4 dependence for infectivity of laboratory-
adapted and primary patient isolates of human immunodefi-
ciency virus type 1. J. Virol. 68:2570–2577.
69. Kozak, S.L., E.J. Platt, N. Madani, F.E. Ferro, K. Peden, and
D. Kabat. 1997. CD4, CXCR-4 and CCR-5 dependencies
for infections by primary patient and laboratory-adapted iso-
lates of human immunodeficiency virus type 1. J. Virol. 71:
873–882.
70. McInerney, T.L., L. McLain, S.J. Armstrong, C.F. Barbas III,
D.R. Burton, and N.J. Dimmock. 1997. A human IgG1
(b12) specific for the CD4 binding site of HIV-1 neutralizes
by inhibiting the virus fusion entry process, but b12 Fab neu-
tralizes by inhibiting a post-fusion event. Virology. 233:313–326.
71. Srivastava, K.K., R. Fernandez-Larsson, D.M. Zinkus, and
H.L. Robinson. 1991. Human immunodeficiency virus type
1 NL4-3 replication in four T-cell lines: rate and efficiency of
entry, a major determinant of permissiveness. J. Virol. 65:
3900–3902.
72. Demaria, S., and Y. Bushkin. 1996. Soluble CD4 induces the
binding of human immunodeficiency virus type 1 to cells via
the V3 loop of glycoprotein 120 and specific sites in glyco-
protein 41. AIDS Res. Hum. Retroviruses. 12:281–290.
73. Demaria, S., S.A. Tilley, A. Pinter, and Y. Bushkin. 1995.
Bathophenanthroline disulfonate and soluble CD4 as probes
for early events of HIV-1 entry. AIDS Res. Hum. Retroviruses.
11:127–139.